Merck Unit Loses $2.5B Verdict As Hep C Patent Invalidated

Law360 (February 16, 2018, 9:38 PM EST) -- A Delaware federal judge dismantled a Merck & Co. unit’s $2.5 billion jury verdict win over Gilead Sciences Inc. in an infringement suit over a hepatitis C drug patent, finding Friday that the patent’s claims weren’t specific enough for an experienced scientist to successfully re-create the formula.

U.S. District Judge Leonard P. Stark ruled that Idenix Pharmaceuticals LLC’s patent for an element of a hepatitis C treatment wasn’t “enabled,” meaning that a person of ordinary skill in the art of drugmaking couldn’t follow the instructions in...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.